Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (LCTX)
:LCTX
LCTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.37 - $1.21
Previous CloseN/A
Volume522.43K
Average Volume (3M)2.49M
Market Cap
$224.79M
Enterprise Value$55.05M
Total Cash (Recent Filing)$47.91M
Total Debt (Recent Filing)$2.24M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 12, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding228,356,300
10 Day Avg. Volume1,364,596
30 Day Avg. Volume2,489,090
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.24
Enterprise Value/Revenue5.76
Enterprise Value/Gross Profit5.93
Enterprise Value/Ebitda-2.64
Forecast
1Y Price Target
$3.80Price Target Upside287.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical ProgressLineage Cell Therapeutics announced the successful delivery of OPC1 to its first patient in the DOSED Study evaluating the novel parenchymal delivery device in spinal cord injury.
Financial StabilityLineage has also taken steps to shore up its balance sheet with runway into 2027, and combined with more favorable market conditions in Biotech, the discount rate is lowered to 30%, from 35%.
Bears Say
Market CompetitionUnprecedented data continue to excite in a big way vs. approved GA products.
Operational ChallengesThe study aims to improve on previous positive clinical effects in SCI patients, with a focus on safety and tolerability as primary and secondary endpoints.
Lineage Therap News
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $0.36 and its highest was $1.21 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $224.79M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2025 which is tomorrow.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on May 13, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.026 by $0.006.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 228,356,300 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.026. Following the earnings report the stock price went down -2.128%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LCTX
Lineage Therap Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.80 (287.76% Upside)
$3.80 (287.76% Upside)
Hedge Fund Trend
Decreased
By 6.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.81%
12-Months-Change
Fundamentals
Return on Equity
-21.40%
Trailing 12-Months
Asset Growth
3.01%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
LCTX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant progress in OpRegen and OPC1 programs, coupled with a major manufacturing milestone that positions Lineage for further growth and partnerships. However, uncertainties around Genentech's decision-making timeline and data access, alongside potential enrollment challenges for OPC1, present notable concerns.View all LCTX earnings summariesLCTX Stock 12 Month Forecast
Average Price Target
$3.80
▲(287.76% Upside)
Technical Analysis
Cellectis SA
―
Editas Medicine
―
Nkarta
―
Neumora Therapeutics, Inc.
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
58.68% Insiders
6.19% Mutual Funds
0.03% Other Institutional Investors
30.82% Public Companies and
Individual Investors